Abstract:Over the past decade, advancements in PET imaging and cerebrospinal fluid biomarkers (CSF) have significantly enhanced the diagnosis of Alzheimer′s disease (AD) by facilitating the early detection of brain amyloidosis (Aβ+). This progress has been crucial for patient management and the administration of new anti-amyloid immunotherapies. Recently, blood biomarkers, particularly phosphorylated tau (pTau) isoforms such as pTau181 and pTau217, have demonstrated high performance in identifying Aβ+. pTau217 was notably used in a ′two-step′ workflow that involves defining two cutoff values within a population: one indicating a high probability of being Aβ+ and another indicating a low probability. The approach′s effectiveness is assessed by minimizing the ′intermediate′ or uncertain zone between these cutoffs. While CSF Aβ42/40 and pTau181/Aβ42 ratios have shown superior accuracy in detecting AD, due to their ability to mitigate confounding factors and reflect disease neuropathology, blood-based biomarker ratios remain underexplored. In this study, conducted within the multicentric ALZAN cohort of patients consulting memory clinics, we compared individual blood biomarker performance with ratios between them, focusing on Aβ40, Aβ42, pTau181 and pTau217. We found the ratios of either pTau isoform to Aβ42, outperformed individual biomarkers in detecting Aβ+, particularly in the early stages of cognitive decline. The pTau181/Aβ42 ratio was as accurate as pTau217, with AUC of 0.911 (0.880-0.936), while the pTau217/Aβ42 ratio outperformed all, with an AUC of 0.927 (0.898-0.950). Using pTau217/Aβ42 instead of pTau217 reduced the proportion of patients classified as intermediate (uncertain) risk for Aβ+ from 16% to 8% in the two-step workflow. These findings provide a practical non-invasive tool to improve early AD detection and treatment decisions.

The ratio of plasma pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosis